These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Lee H; Hamilton JR Pharmacol Ther; 2012 May; 134(2):246-59. PubMed ID: 22327235 [TBL] [Abstract][Full Text] [Related]
3. Proteinase-activated receptors (PARs) as targets for antiplatelet therapy. Cunningham M; McIntosh K; Bushell T; Sloan G; Plevin R Biochem Soc Trans; 2016 Apr; 44(2):606-12. PubMed ID: 27068977 [TBL] [Abstract][Full Text] [Related]
4. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179 [TBL] [Abstract][Full Text] [Related]
5. Protease-activated receptors as targets for antiplatelet therapy. Hamilton JR Blood Rev; 2009 Mar; 23(2):61-5. PubMed ID: 18644663 [TBL] [Abstract][Full Text] [Related]
7. Protease activated receptors: clinical relevance to hemostasis and inflammation. Landis RC Hematol Oncol Clin North Am; 2007 Feb; 21(1):103-13. PubMed ID: 17258121 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases. Bulani Y; Sharma SS Curr Pharm Des; 2015; 21(30):4392-9. PubMed ID: 26471318 [TBL] [Abstract][Full Text] [Related]
9. Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When? Li S; Tarlac V; Hamilton JR Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717963 [TBL] [Abstract][Full Text] [Related]
10. Protease-activated receptors in cardiovascular health and diseases. Shah R Am Heart J; 2009 Feb; 157(2):253-62. PubMed ID: 19185631 [TBL] [Abstract][Full Text] [Related]
11. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. French SL; Arthur JF; Tran HA; Hamilton JR Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961 [TBL] [Abstract][Full Text] [Related]
13. Vorapaxar for the reduction of atherothrombotic events. Diaz-Ricart M; Escolar G Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635 [TBL] [Abstract][Full Text] [Related]
14. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. Leonardi S; Becker RC Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734 [TBL] [Abstract][Full Text] [Related]
16. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Hollenberg MD; Oikonomopoulou K; Hansen KK; Saifeddine M; Ramachandran R; Diamandis EP Biol Chem; 2008 Jun; 389(6):643-51. PubMed ID: 18627296 [TBL] [Abstract][Full Text] [Related]
17. Proteinase activated receptor (PAR) involvement in mediating arthritis pain and inflammation. Russell FA; McDougall JJ Inflamm Res; 2009 Mar; 58(3):119-26. PubMed ID: 19184346 [TBL] [Abstract][Full Text] [Related]
18. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions. Lee H; Sturgeon SA; Jackson SP; Hamilton JR Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047 [TBL] [Abstract][Full Text] [Related]
19. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Zeidner JF; Frishman WH; Lerner RG Cardiol Rev; 2008; 16(5):250-9. PubMed ID: 18708826 [TBL] [Abstract][Full Text] [Related]